Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 75261

Title: Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report and literature review

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05455317
Position: Peer Reviewer
Academic degree: PhD

Professional title: Associate Professor, Senior Scientist

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2022-01-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-29 03:10

Reviewer performed review: 2022-02-08 15:35

Review time: 10 Days and 12 Hours

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [ ] Anonymous [Y] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Gist/Summary: The authors come up with a very interesting case study reporting a patient with EGFR delE709_T710insD after the initiation of dacomitinib. The case study is very well interpreted and the efficacy of dacomitinib on rare mutations needs was interpreted using the genetic analysis albeit to be validated using in vitro and in vivo I only wish the authors delve upon the cell block samples and PCR as the authors were not clear on the results interpreting the PCR. There could be a table mentioining the same. Am I missing anything? Otherwise a very much needed case for clinical community

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 75261

Title: Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report and literature review

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03908850
Position: Peer Reviewer
Academic degree: BSc, MD
Professional title: Doctor, Research Scientist, Staff Physician, Surgeon, Surgical Oncologist
Reviewer's Country/Territory: Russia
Author's Country/Territory: China

Manuscript submission date: 2022-01-22

Reviewer chosen by: Xin Liu (Online Science Editor)

Reviewer accepted review: 2022-03-07 16:02

Reviewer performed review: 2022-03-07 16:48

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thank you for the possibility to review the manuscript titled "Response to dacomitinib in advanced NSCLC harboring the rare delE709_T710insD mutation: A case report and literature review". The study is interesting and easy to read. Moreover, the study underlines new and important data for clinical practice. delE709_T710insD is present in only 0.16% of cases, which means that the drug can be used in a limited number of cases. Nevertheless, the case report is important to consider for publication. The are no major or minor recommendations.